STOCK TITAN

Longeveron Inc - LGVN STOCK NEWS

Welcome to our dedicated news page for Longeveron (Ticker: LGVN), a resource for investors and traders seeking the latest updates and insights on Longeveron.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Longeveron's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Longeveron's position in the market.

Rhea-AI Summary
Longeveron Inc. (NASDAQ: LGVN) will be presenting at the Planet MicroCap Showcase on May 1-2, 2024. The presentation will take place on May 1, 2024, at 4:30 p.m. PT. Investors can register for 1x1 meetings with the company and attend the showcase in person at the Paris Hotel & Casino in Las Vegas, NV.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary
Longeveron Inc. (NASDAQ: LGVN) announced the closing of its warrant exercise offering and public offering, raising a total of $11.4 million in gross proceeds. The funding will be used to advance the HLHS program, including ongoing clinical trials for conditions like Alzheimer's disease and Aging-related Frailty. The Company issued new unregistered warrants to purchase up to 4,799,488 shares of Class A common stock, with gross proceeds of approximately $6.2 million from the warrant exercise offering and $5.2 million from the public offering. The net proceeds will support clinical and regulatory development, obtaining regulatory approvals, capital expenditures, working capital, and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.48%
Tags
-
Rhea-AI Summary
Longeveron Inc. (NASDAQ: LGVN) announced the exercise of warrants for $6.2 million gross proceeds. The company entered into agreements for the exercise of 2,399,744 shares of its Class A common stock at an exercise price of $2.35 per share. H.C. Wainwright & Co. is the exclusive placement agent for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-40.79%
Tags
none
Rhea-AI Summary
Longeveron Inc. (NASDAQ: LGVN) announces that its CLEAR MIND Phase 2a clinical trial evaluating Lomecel-B™ in mild Alzheimer’s Disease has been accepted for a Featured Research Oral Presentation at the 2024 Alzheimer’s Association International Conference. The company will also present a poster at the conference. CEO Wa’el Hashad expresses excitement for sharing the study results at the leading forum for Alzheimer’s disease clinical investigation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
73.37%
Tags
-
Rhea-AI Summary
Longeveron Inc. (LGVN) closes public offering, raising $5.2 million for clinical and regulatory development of Lomecel-B™. Board members and insiders participate in the offering. The Company also amends existing warrants to lower exercise price and extend expiration dates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.34%
Tags
-
Rhea-AI Summary
Longeveron Inc. announces a public offering of 2,234,043 shares of Class A common stock and warrants at $2.35 per share, aiming to raise capital for the development of cellular therapies for various conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.27%
Tags
Rhea-AI Summary
Longeveron Inc. (LGVN) CEO updates shareholders on strategic roadmap and key priorities for 2024, focusing on regenerative medicine development. The company's lead product, Lomecel-B™, shows promise in treating Hypoplastic Left Heart Syndrome (HLHS) and Alzheimer’s Disease, with positive trial results and FDA designations. Longeveron aims for HLHS commercialization, strategic collaborations, efficient resource management, and financial stewardship.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.27%
Tags
none
-
Rhea-AI Summary
Longeveron Inc. (LGVN) announces a 1-for-10 reverse stock split to increase per-share trading price and regain Nasdaq compliance. The split will convert every ten shares into one, reducing outstanding shares significantly.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.97%
Tags
-
Rhea-AI Summary
Longeveron Inc. announces 2024 strategic priorities focusing on advancing Lomecel-B™ in HLHS and Alzheimer’s disease. The company presented long-term survival data from ELPIS I trial at the American Heart Association, with additional clinical data from CLEAR MIND Phase 2a trial in Alzheimer’s disease. Financially, revenues decreased by 42% in 2023, with a gross profit decrease of 56%. General and administrative expenses increased by 40%, while research and development expenses decreased by 3%. Net loss increased by 14% in 2023. The company discontinued its Aging-related Frailty clinical trial in Japan to focus on HLHS and Alzheimer’s disease programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.99%
Tags
none
Rhea-AI Summary
Longeveron Inc. (LGVN) will report its 2023 financial results on February 27, 2024, followed by a conference call to discuss the results and provide a business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.02%
Tags
conferences
Longeveron Inc

Nasdaq:LGVN

LGVN Rankings

LGVN Stock Data

5.37M
1.13M
6.71%
14.27%
1.12%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Miami

About LGVN

longeveron llc is a leading global regenerative medicine company developing innovative cellular therapeutics for chronic life-threatening diseases. our lead investigational product candidate (lmsc) is based on a specialized cell known as a mesenchymal stem cell that is derived from the bone marrow of healthy young adult donors. our allogeneic, ‘off-the-shelf’ product is under investigation for chronic conditions of the elderly, and other life- threatening diseases, for which no approved therapeutics currently exist: • aging frailty syndrome • alzheimer’s disease • hypoplastic left heart syndrome • the metabolic syndrome